October 10, 2011
Eisai and Abbott Japan announced on September 26 that they applied on the same day for an additional indication of inhibition of structural damage of joints in rheumatoid arthritis (RA) for the humanized anti-human TNFƒ¿ monoclonal antibody Humira (adalimumab). The...read more